Cardarine comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-02-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport; not approved as medicine | Listed by WADA at all times. |
| Common synonyms | GW501516, GW-501516, endurobol | Cardarine is a colloquial name. |
| Typical analytical method | LC-MS/MS | Detects parent compound and metabolites. |
| Common test matrix | Urine | Blood and dried blood spots also possible. |
| Legal classification | Varies by country | Often treated as unapproved drug or research chemical. |
GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.
Detection of GW501516 in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. Urine is a common matrix in anti-doping analysis, while blood or plasma may be used in research settings. Sample preparation can involve enzymatic hydrolysis, protein precipitation, or solid-phase extraction before instrumental analysis. Because the compound undergoes metabolism, assays may target the parent molecule, one or more metabolites, or both. Detection windows are not fixed; they depend on factors such as dose, route, individual metabolism, and assay sensitivity. Reference standards are required for accurate identification and quantification.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
== Use == The thomson has been used by some mass spectrometrists, for example Alexander Makarov—the inventor of the Orbitrap—in a scientific poster, and a 2015 presentation. Other uses of the thomson include papers, and (notably) one book. The journal Rapid Communications in Mass Spectrometry (in which the original article appeared) states that "the thomson (Th) may be used for such purposes as a unit of mass-to-charge ratio although it is not currently approved by IUPAP or IUPAC." Even so, the term has been called "controversial" by RCM's former editor-in-chief (in a review the Hoffman text cited above). The book, Mass Spectrometry Desk Reference, argues against the use of the thomson. However, the editor-in-chief of the Journal of the Mass Spectrometry Society of Japan has written an editorial in support of the thomson unit. The thomson is not an SI unit, nor has it been defined by IUPAC. Since 2013, the thomson is deprecated by IUPAC (Definitions of Terms Relating to Mass Spectrometry). Since 2014, Rapid Communications in Mass Spectrometry regards the thomson as a "term that should be avoided in mass spectrometry publications".
==== China ==== In China a number of think tanks are sponsored by governmental agencies such as Development Research Center of the State Council, but still retain sufficient non-official status to be able to propose and debate ideas more freely. In January 2012, the first non-official think tank in mainland China, South Non-Governmental Think-Tank, was established in the Guangdong province. In 2009 the China Center for International Economic Exchanges was founded.
==== 1998–1999 ==== On August 7, 1998, Andrés Pastrana Arango was sworn in as the President of Colombia. A member of the Conservative Party, Pastrana defeated Liberal Party candidate Horacio Serpa in a run-off election marked by high voter turn-out and little political unrest. The new president's program was based on a commitment to bring about a peaceful resolution of Colombia's longstanding civil conflict and to cooperate fully with the United States to combat the trafficking of illegal drugs. In July 1999, Colombian military forces attacked the town of Puerto Lleras where FARC rebels were stationed. Using U.S. supplied aircraft and equipment, and backed with U.S. logistical support, Colombian government forces strafed and bombed the town for over 72 hours. In the attack, three civilians were killed and several others were wounded as the military attacked hospitals, churches, ambulances, and residential areas. FARC rebels were forced to flee the area and many were killed or wounded. The Colombian government claimed that this was a significant victory, while human rights groups claimed this was proof that "anti-narcotics" aid was actually just military aid being used to fight a leftist insurgency.
Sources: en.wikipedia.org
== Research and contributions == Sheiner's research focused on developing mathematical models and data analysis techniques to quantitatively characterize the impact of drug therapy from observational data, gathered either during drug development trials or during routine patient care. The practical objective motivating his research was more efficient and informative clinical trials as well as the ability to optimize dosage recommendations for individual patients. His work has influenced clinical pharmacology as a scientific discipline as well as the pharmaceutical industry and drug regulation more broadly. Sheiner's models have been implemented via software such as NONMEM, co-developed with Barr Rosenberg. Among his many notable papers are "Modelling of individual pharmacokinetics for computer-aided drug dosage" in 1972, "Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models" co-written with Nick Holford in 1981, and "Learning versus confirming in clinical drug development" in 1997.
The structure of hemoglobins varies across species. Hemoglobin occurs in all kingdoms of organisms, but not in all organisms. Primitive species such as bacteria, protozoa, algae, and plants often have single-globin hemoglobins. Many nematode worms, molluscs, and crustaceans contain very large multisubunit molecules, much larger than those in vertebrates. In particular, chimeric hemoglobins found in fungi and giant annelids may contain both globin and other types of proteins. One of the most striking occurrences and uses of hemoglobin in organisms is in the giant tube worm (Riftia pachyptila, also called Vestimentifera), which can reach 2.4 meters length and populates ocean volcanic vents. Instead of a digestive tract, these worms contain a population of bacteria constituting half the organism's weight. The bacteria oxidize H2S from the vent with O2 from the water to produce energy to make food from H2O and CO2. The worms' upper end is a deep-red fan-like structure ("plume"), which extends into the water and absorbs H2S and O2 for the bacteria, and CO2 for use as synthetic raw material similar to photosynthetic plants. The structures are bright red due to their content of several extraordinarily complex hemoglobins that have up to 144 globin chains, each including associated heme structures. These hemoglobins are remarkable for being able to carry oxygen in the presence of sulfide, and even to carry sulfide, without being completely "poisoned" or inhibited by it as hemoglobins in most other species are.
The 43-second "Iron Gland" was developed out of a guitar riff that Cantrell would play that annoyed the other band members, so he created the song (adding in a reference to Black Sabbath's "Iron Man") and promised to never play the guitar riff again. It features Tom Araya of thrash metal band Slayer on vocals, as well as Layne Staley. "Hate to Feel" and "Angry Chair" were both composed solely by Staley, who also played guitar on both tracks, and Cantrell has expressed his pride in seeing Staley grow as a songwriter and guitarist. "Down in a Hole" was written by Cantrell to his long-time girlfriend, Courtney Clarke. Cantrell explained the song in the liner notes of 1999's Music Bank box set: "["Down in a Hole"]'s in my top three, personally. It's to my long-time love. It's the reality of my life, the path I've chosen and in a weird way it kind of foretold where we are right now. It's hard for us to both understand... that this life is not conducive to much success with long-term relationships." The album's final track, "Would?", was written by Cantrell as a tribute to his friend and late lead singer of Mother Love Bone, Andrew Wood, who died of a drug overdose in 1990. Cantrell said the song is also "directed towards people who pass judgments."
Sources: en.wikipedia.org
We used to read this same atavistic proclamation by the hellish light of burning Sarajevo, and now we glimpse it again through the flames of the blazing U.S. Embassy in Belgrade, and by the glare of similar but less dramatic arsons set by Serbs in ski masks in northern Kosovo itself. But it needs to be understood that "Serbia" itself has lost nothing and has nothing to complain about. With the independence of Kosovo, the Yugoslav idea is finally and completely dead, but it was Serbian irredentism that killed the last vestige of that idea, and it is to that account that the whole cost ought to be charged. Forget all the nonsense that you may have heard about Kosovo being "the Jerusalem" of Serbia. It may contain some beautiful and ancient Serbian and Serbian Orthodox cultural sites, but it is much more like Serbia's West Bank or Gaza, with a sweltering, penned-up, subject population who were for generations treated as if they were human refuse in the land of their own birth. Nobody who has spent any time in the territory, as I did during and after the eviction of the Serb militias, can believe for a single second that any Kosovar would ever again submit to rule from Belgrade. It's over.
== Controversies == Holick has been involved in several medical controversies. While at Boston University, he was asked to leave the Division of Dermatology because of his promoting the medical benefits of sun exposure. He accepted research funding for this work from a non-profit tanning bed company, considered by many to be an important potential bias. Barbara Gilchrest, then head of the department at Boston University, called Holick's book "shlock science" and Holick "a poster boy for the tanning industry". Holick received nearly $163,000 from 2013 to 2017 from pharmaceutical companies, according to Medicare’s Open Payments database, which tracks payments from drug and device manufacturers. The companies paying him included Sanofi-Aventis, which markets vitamin D supplements; Shire, which makes drugs for hormonal disorders that are given with vitamin D; Amgen, which makes an osteoporosis treatment; and Roche Diagnostics and Quidel Corp., which both make vitamin D tests. Holick has also been criticized by other physicians because of his testimony, defending accused child abusers by asserting that Ehlers–Danlos syndrome is a cause of non-traumatic fractures in infancy (rather than abuse). In one case of a child who had suffered broken bones in which Holick defended the accused parent, the child later went on to suffer severe brain injury, for which the parent, named Robert Marvin Ray, has been indicted.
PEGylation as a method to improve half-life has been successfully demonstrated many times; in one example it shows that site specific mono-PEGylation of GLP-1 led to a 16-fold increase in plasma half-life time in rats. On the other hand, covalently attaching PEG can often lead to loss of biological activity. Another chemical modification is the attachment of glycosyl (carbohydrate) units to the peptide to help with peptide delivery to target sites. The introduction of carbohydrates to peptides can alter the physiological properties, to improve bioavailability. Advantages of this technique include increased metabolic stability, and facilitated transport across cell membranes, although of the most favourable aspects is their ability to promote oral absorption. Peptides have a very low oral availability (less than 1–2%), as a result of insufficient absorption and rapid degradation and clearance, thus making this method an attractive one. N- and O-glycosylation in which carbohydrates are attached to the peptide are naturally occurring, where N-glycosylation occurs through the amine group of an asparagine residue to form an amide bond. O-glycosylation occurs via serine or threonine residues, where the oxygen atom on the side chain binds to the carbohydrate through an ether bond. There is also non-natural glycosylation, known as chemical glycosylation, which involves the attachment of carbohydrate units to different amino acid residues at the N-terminus of the peptide's sequence.
On the other hand, by inhibiting miR-33 function, the level of ABCA1 is increased, which increases the cholesterol efflux to apoA-1. Suppression of miR-33 will lead to less cellular cholesterol and higher plasma HDL level through the regulation of ABCA1 expression.
Sources: en.wikipedia.org
Legal status varies by country. It is not approved as a medicine, and it is prohibited in sport. Some jurisdictions restrict import, sale, or possession.
Laboratories use liquid chromatography-tandem mass spectrometry to detect GW501516 and its metabolites. Urine is commonly tested, and testing can occur in and out of competition.
No, cardarine is not a SARM. It is a PPARδ agonist, which acts on a different receptor. The two classes are often confused in online discussions.
It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.